放射性标记的抗人乳脂肪球膜抗原单克隆抗体在抗体引导肿瘤显像中的应用，以及标记抗体治疗剂量在广泛播散性卵巢癌中的应用。初步报告。

The use of radiolabelled monoclonal antibodies to human milk fat globule membrane antigens in antibody-guided tumour imaging, and administration of therapeutic dose of labelled antibody in wide-spread ovarian carcinoma. A preliminary report.

作者信息

Ashorn R, Ashorn P, Punnonen R, Pöyhönen L, Turjanmaa V, Koskinen M, Helle M, Uusitalo A, Pystynen P, Krohn K

出版信息

Ann Chir Gynaecol Suppl. 1985;197:5-10.

Abstract

Monoclonal antibodies generated against human milk fat globule membrane antigens were used in antibody-guided tumour imaging and palliative therapy in a case of wide-spread ovarian carcinoma. Antibody III H 2, which previously has been shown to react with 100% of ovarian cystadenocarcinomas showed a strong reactivity with tissue sections obtained from the primary and metastatic tumours of the patient. Immunoglobulins were purified from mouse ascitic fluid containing III H 2 and labelled with 123I or 131I with the iodogen method. 80 MBq (2 mCi) of 123I-labelled antibody was given intraperitoneally in 500 ml of PBS and the uptake of radiolabel was followed daily with emission tomography. Radiolabel was mainly located in the peritoneal cavity; only a very low activity was seen in the thyroid gland and urinary bladder. A therapeutic dose consisting of 600 MBq (15 mCi) of 131I-labelled antibody was followed nine days later and the localization of the antibody was followed.

摘要

针对人乳脂肪球膜抗原产生的单克隆抗体被用于广泛播散性卵巢癌病例的抗体导向肿瘤成像和姑息治疗。抗体III H 2先前已被证明能与100%的卵巢囊腺癌发生反应，它与从该患者的原发性和转移性肿瘤获取的组织切片呈现出强烈的反应性。从含有III H 2的小鼠腹水中纯化免疫球蛋白，并用碘代法用123I或131I进行标记。将80 MBq（2 mCi）的123I标记抗体溶于500 ml PBS中经腹腔注射，每天用发射断层扫描追踪放射性标记的摄取情况。放射性标记主要位于腹腔；仅在甲状腺和膀胱中观察到极低的活性。九天后给予由600 MBq（15 mCi）的131I标记抗体组成的治疗剂量，并追踪抗体的定位情况。